Short Term Rating on Lannett Co Inc (LCI)

Lannett Co Inc (LCI) : 6 analysts are covering Lannett Co Inc (LCI) and their average rating on the stock is 1.83, which is read as a Buy. 3 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. Lannett Co Inc (LCI) also receives 1 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 2, which recommends a Buy affirms that they expect a large upside in the stock from the current levels. A total of 2 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Lannett Co Inc (LCI) : Currently there are 4 street experts covering Lannett Co Inc (LCI) stock. The most bullish and bearish price target for the stock is $35 and $26 respectively for the short term. The average price target of all the analysts comes to $29.88. The estimated standard deviation from the target is $4.01.

For the current week, the company shares have a recommendation consensus of Buy.


Lannett Co Inc (NYSE:LCI): The stock opened at $27.75 on Tuesday but the bulls could not build on the opening and the stock topped out at $27.81 for the day. The stock traded down to $26.82 during the day, due to lack of any buying support eventually closed down at $27.51 with a loss of -0.76% for the day. The stock had closed at $27.72 on the previous day. The total traded volume was 1,054,001 shares.

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Companys products include Levothyroxine Sodium tablets, Digoxin tablets, Butalbital products, Ursodiol capsules and pain management products. Levothyroxine Sodium tablets are produced and marketed with around 12 varying potencies. Digoxin tablets are produced and marketed with approximately two different potencies. It distributes around three products containing Butalbital. Ursodiol capsules are produced and marketed in 300 milligram capsules. The Company offers a range of pain management products, such as Cocaine Topical Solution (C-Topical), Morphine Sulfate Oral Solution, Hydromorphone hydrochloric acid (HCl) tablets and Codeine Sulfate tablets.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.